TABLE 4.
Outcome | No Ipilimumab (n = 91) | Concurrent Ipilimumab (n = 59) | Nonconcurrent Ipilimumab (n = 160) | p Value |
---|---|---|---|---|
Local failure | 17 (19%) | 6 (10%) | 30 (19%) | 0.26 |
Lesion hemorrhage | 13 (14%) | 19 (32%) | 24 (15%) | 0.01 |
Symptomatic | 5 (5%) | 3 (5%) | 6 (4%) | 0.76 |
TRIC | 7 (8%) | 8 (14%) | 17 (11%) | 0.50 |
Symptomatic | 0 (0%) | 5 (8%) | 9 (6%) | 0.005 |
RN | 0 (0%) | 2 (3%) | 3 (2%) | 0.22 |
Values are shown as the number of lesions (%) unless otherwise indicated.